Loading clinical trials...
Loading clinical trials...
The purpose of this study is to test the safety and tolerability of IMGN529 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
ImmunoGen, Inc.
NCT06846671 · CLL, Chronic Lymphocytic Leukemia
NCT07218341 · Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
NCT06548152 · Chronic Lymphocytic Leukemia
NCT07030400 · Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL)
NCT05006716 · B-cell Malignancy, Marginal Zone Lymphoma, and more
Dana Farber Cancer Institute
Boston, Massachusetts
Memorial Sloan-Kettering Cancer Center
New York, New York
Ohio State University
Columbus, Ohio
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions